StevanatoSTVN
About: Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Employees: 5,521
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
52% more call options, than puts
Call options by funds: $41K | Put options by funds: $27K
7% more capital invested
Capital invested by funds: $1.19B [Q4 2024] → $1.27B (+$86.6M) [Q1 2025]
5% more funds holding
Funds holding: 129 [Q4 2024] → 136 (+7) [Q1 2025]
2% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 47
4.48% less ownership
Funds ownership: 110.05% [Q4 2024] → 105.56% (-4.48%) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for STVN.
Financial journalist opinion
Based on 3 articles about STVN published over the past 30 days
